CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Oxytocin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03610633
NCT03610633Phase 2Completed
CompareCT.gov

Impact of Oxytocin on Neurobiologic Substrates of Social Stress in Individuals With Alcohol Use Disorder

Medical University of South Carolina·interventional·Posted Aug 1, 2018·Updated Oct 23, 2019

In Brief

A Phase 2 clinical trial evaluating Oxytocin and Placebo for Alcohol Use Disorder. Completed, enrolled 11 participants across 1 site.

Detailed Summary

Individuals with alcohol use disorder (AUD) will complete one functional Magnetic Resonance Imaging (fMRI) scanning visit. Prior to the scan, individuals will receive a nasal spray of either 24 international units (IU) of oxytocin (OT), or placebo (PBO). During the scan, they will perform the Montreal Imaging Stress Task (MIST), a social stress task. Subjective craving and anxiety data will be collected.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 1, 2018
Enrollment StartMar 1, 2016
Primary CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.9 years ago

Interventions

Oxytocindrug

The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.

Placebodrug

Saline solution.